Effectiveness of Meropenem-Levofloxacin with Meropenem-Amikasin Towards LOS & Leukocytes to RASPRO III Stratification Community Pneumonia Patients
Abstract
Administration of antibiotics in the private hospital "X" adopted a concept called Ronald
Irwanto Antimicrobial Steweardship Program (RASPRO). The suggestion of an empirical antibiotic
combination in type III stratifi cation community pneumonia patients was meropenem-levofl oxacin
or meropenem-amikasin. The aim of the study was to determine the eff ect of empirical antibiotic
combination meropenem-levofl oxacin with meropenem-amikacin to RASPRO type III stratifi cation
community pneumonia patients towards the LOS and decreased leukocytes. The test sample calculated
using diff erence between two population proportions formula and analysed using Chi-square method.
Diabetes mellitus, immobilisation and geriatrics as confounding variables were controlled by logistic
regretion multivariate analysis. The results showed that meropenem-levofl oxacin had a tendency 1.81
times to experience LOS < 5 days and 0.92 times to experience decreased leukocytes ≥ 10% compared
to meropenem-amikacin, but both were not signifi cant (p 0.161 and p 0.835). The result control of
confounding variables were found that geriatrics as a meaningful confounding variable eff ect of LOS
and no confounding variables were considered to aff ect the decreased leukocytes. In conclusion, there
is no eff ect of empirical antibiotic combination meropenem-levofl oxacin with meropenem-amikacin
towards the LOS and decreased leukocytes to RASPRO type III stratifi cation community pneumonia
patients using statistics after controlling the confounding variables.
References
Jakarta: RS "X"; 2017.
2. Irwanto R. Konsep RASPRO: Metode Tataguna
Antibiotik Bijak Dalam Rangka Menjalankan Fungsi
PPRA di Rumah Sakit.
3. Kalil AC, Metersky ML, Klompas M, Muscedere J,
Sweeney DA, Palmer LB, Napolitano LM, O'Grady
NP, Bartlett JG, Carratalà J, El Solh AA. Management
of adults with hospital-acquired and ventilatorassociated
pneumonia: 2016 clinical practice
guidelines by the Infectious Diseases Society of
America and the American Thoracic Society. Clinical
Infectious Diseases. 2016. 63(5):e61-111.
4. Tamma PD, Cosgrove SE, Maragakis LL. Combination
therapy for treatment of infections with gram-negative
bacteria. Clinical microbiology reviews. 2012.
25(3):450-70.
5. Yayan J, Ghebremedhin B, Rasche K. Antibiotic
resistance of Pseudomonas aeruginosa in pneumonia
at a single university hospital center in Germany over
a 10-year period. Plos one. 2015. 10(10).
6. Perhimpunan Dokter Paru Indonesia. Pneumonia
Komuniti. 2003. 1-24.
7. Perhimpunan Dokter Paru Indonesia. Pneumonia
Komuniti edisi II. 2014. 1-52.
8. Mandell LA, Wunderink RG, Anzueto A, Bartlett
JG, Campbell GD, Dean NC, Dowell SF, File Jr TM,
Musher DM, Niederman MS, Torres A. Infectious
Diseases Society of America/American Thoracic
Society consensus guidelines on the management of
community-acquired pneumonia in adults. Clinical
infectious diseases. 2007.44(Supplement_2):27-72.
9. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek
J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders
SA, Griffi n MR. Diagnosis and treatment of adults
with community-acquired pneumonia. An offi cial
clinical practice guideline of the American Thoracic
Society and Infectious Diseases Society of America.
American journal of respiratory and critical care
medicine. 2019. 200(7):e45-67.
10. Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P,
Gaito S, Ramirez JA. Duration of antibiotic therapy
in hospitalised patients with community-acquired
pneumonia. European Respiratory Journal. 2010.
36(1):128-34.
11. American Thoracic Society. Guidelines for the
management of adults with community-acquired
pneumonia, Diagnosis, assessment of severity,
antimicrobial therapy, and prevention. Am J Respir
Crit Care Med. 2001. 163:1730-54.
12. Widasari N. Pola Derajat Keparahan Pneumonia dan
Terapi Antibiotik Empirik pada Pasien Communityacquired
Pneumonia (CAP) yang Dirawat di RSUP Dr.
Kariadi Semarang: Fakultas Kedokteran Universitas
Diponegoro. 2014.
13. Sari MA, Raveinal R, Noverial N. Derajat Keparahan
Pneumonia Komunitas pada Geriatri Berdasarkan
Skor CURB-65 di Bangsal Penyakit Dalam RS. Dr.
M. Djamil Padang Tahun 2016. Jurnal Kesehatan
Andalas. 2018. 7(1):102-7.
14. Center for Research Integrated Development of Tropical
Health and Infectious Diseases [Internet]. 2014 [cited
2020 Mar 12]. Available from: http://tropicinfection.
ui.ac.id/data/index.php?uPage=dashboard.grafi k_det
_g&smod=dashboard&sp=public&idpenelitian=8850
15. Welte T, Torres A, Nathwani D. Clinical and economic
burden of community-acquired pneumonia among
adults in Europe. Thorax. 2012. 67(1):71-9.
16. Mulyana R. Terapi Antibiotika pada Pneumonia Usia
Lanjut. Jurnal Kesehatan Andalas. 2019. 8(1):172-7.
17. Cabre M, Bolivar I, Pera G, Pallares R. Factors
infl uencing length of hospital stay in communityacquired
pneumonia: a study in 27 community hospitals.
Epidemiology & Infection. 2004. 132(5):821-9.
18. Torres A, Peetermans WE, Viegi G, Blasi F. Risk
factors for community-acquired pneumonia in
adults in Europe: a literature review. Thorax. 2013.
68(11):1057-65.
19. Medscape. Amikacin [Internet]. 2020 [cited 2020 Mar
12]. Available from: https://reference.medscape.com/
drug/amikin-amikacin-342516
20. Kementerian Kesehatan Republik Indonesia. Peraturan
Menteri Kesehatan Republik Indonesia Nomor 2406
Tahun 2011 tentang Pedoman Umum Penggunaan
Antibiotik. 2011
21. Informatorium Obat Nasional Indonesia (IONI).
Antibiotik Beta-laktam Lain [Internet]. 2015 [cited
2020 Mar 12]. Available from: http://pionas.pom.go.id/
ioni/bab-5-infeksi/51-antibakteri/512-sefalosporindan-
antibiotik-beta-laktam-lainnya/5122
22. Medscape. Meropenem [Internet]. 2020 [cited 2020
Mar 12]. Available from: https://reference.medscape.
com/drug/merrem-iv-meropenem-342565#10
23. Informatorium Obat Nasional Indonesia (IONI).
Kuinolon [Internet]. 2015 [cited 2020 Mar 12].
Available from: http://pionas.pom.go.id/ioni/bab-5-
infeksi/51-antibakteri/516-kuinolon
24. Medscape. Levofloxacin [Internet]. 2020 [cited
2020 Mar 12]. Available from: https://reference.
medscape.com/drug/levaquin-levofl oxacin-systemiclevofl
oxacin-342532
25. Informatorium Obat Nasional Indonesia (IONI).
Aminoglikosida [Internet]. 2015 [cited 2020 Mar 12].
Available from: http://pionas.pom.go.id/ioni/bab-5-
infeksi/51-antibakteri/514-aminoglikosida
26. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis
G, Falagas ME. Impact of defi nitive therapy with
beta-lactam monotherapy or combination with an
aminoglycoside or a quinolone for Pseudomonas
aeruginosa bacteremia. PLoS One. 2011. 6(10):e26470
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Tools
